A Prospective, Randomized Trial Comparing Combination Half‐Dose Tissue‐Type Plasminogen Activator and Streptokinase With Full-Dose Tissue‐Type Plasminogen Activator
Explore this paper's citation graph
Summary
These results suggest that a less expensive regimen of half-dose t-PA with SK yields superior 90-minute patency and left ventricular function and a trend toward reduced reocclusion compared with the conventional dose of t- PA.
- Type
- article
- Published
- 1991-08-01
- Cited by
- 80
- References
- 42
- Access
- Open access
- OpenAlex
- https://openalex.org/W2021692378
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21627155
Keywords
Medicine, Streptokinase, Thrombolysis, Myocardial infarction, Plasminogen activator
References
- Management of acute myocardial infarction 1990: A perspective
- The thrombolysis in myocardial infarction (TIMI) trial.
- Altered rheological properties of blood following administrations of tissue plasminogen activator and streptokinase in patients with acute myocardial infarction.
- Relevance of changes in blood fibrinolytic and coagulation parameters during thrombolytic therapy.
- Competitions between fibrinogen with its degradation products for interactions with the platelet-fibrinogen receptor.
- Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.
- Prevention of coronary artery reocclusion and reduction in late coronary artery stenosis after thrombolytic therapy in patients with acute myocardial infarction. A randomized study of maintenance infusion of recombinant human tissue-type plasminogen activator.
- Advantages and applications of the centerline method for characterizing regional ventricular function.
- A new thrombolytic regimen for acute myocardial infarction using combination half dose tissue-type plasminogen activator with full dose streptokinase: a pilot study. KAMIT Study Group.
- Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator.
- The use of single plane angiocardiograms for the calculation of left ventricular volume in man.
- A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction.
- Infarct vessel status after intravenous tissue plasminogen activator and acute coronary angioplasty: prediction of clinical outcome.
- Evaluation of the effectiveness of intracoronary streptokinase infusion in acute myocardial infarction: postprocedure management and hospital course in 204 patients.
- Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction.
- Intravenous recombinant tissue-type plasminogen activator in patients with acute myocardial infarction: a report from the NHLBI thrombolysis in myocardial infarction trial.
- Randomized trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Verstraete M, Bory M, Erbel R, et al Lancet 842–847 Apr 13, 1985
- Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS).
- Protection of Myocardial Function and Coronary Vasculature by Streptokinase
- Prognosis after acute myocardial infarction in patients with and without residual anterograde coronary blood flow.
Cited by
- Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques.
- Thrombolytic Therapy: The Treatment of Choice in Acute Myocardial Infarction
- Anthony Nicholas DeMaria, MD: a conversation with the editor. Interview by William Clifford Roberts, MD.
- An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
- The Thrombolysis in Myocardial Infarction (TIMI) trials: the first decade.
- Dynamics in Thrombus Formation
- Thrombolytic therapy: 2001.
- Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis
- Validation of the early open infarct vessel hypothesis.
- Efficacy and safety of low-dose streptokinase plus desmopressin in acute myocardial infarction: A pilot study
- Implications of recurrent ischemia after reperfusion therapy in acute myocardial infarction: a comparison of thrombolytic therapy and primary angioplasty.
- Direct angioplasty versus initial thrombolytic therapy for acute myocardial infarction: long-term follow-up and changes in practice pattern.
- Gender differences in percutaneous interventional therapy of coronary artery disease.
- Influence of acute myocardial infarction location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy.
- Comparison of saruplase and alteplase in acute myocardial infarction. SESAM Study Group. The Study in Europe with Saruplase and Alteplase in Myocardial Infarction.
- Advances in thrombolytic therapy
- Serial angiographic follow-up after successful direct angioplasty for acute myocardial infarction.
- A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group.
- Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction.
- Use of composite endpoints in thrombolysis trials of acute myocardial infarction.
Related papers
- Correlation between Baseline Plasminogen Activator Inhibitor Levels and Clinical Outcome during Therapy with Tissue Plasminogen Activator for Acute Myocardial Infarction
- Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction.
- Analysis of coagulation and fibrinolysis during intravenous infusion of recombinant human tissue-type plasminogen activator in patients with acute myocardial infarction.
- Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits
- Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits.
- RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR(R-TPA)THROMBOLYTIC THERAPY IN 65 PATIENTS WITH MYOCARDIAL INFARCTION